Craft

Advanced
Pharmaxis

Pharmaxis

Stock Price

$0

2023-12-06

Market Capitalization

$20.2 M

2023-12-06

Pharmaxis Summary

Company Summary

Overview
Pharmaxis is a pharmaceutical research company. It is offers respiratory products used in cystic fibrosis and asthma. The company also offers drug development for inflammation and fibrotic diseases.
Type
Public
Status
Active
Founded
1998
HQ
Frenchs Forest, AU | view all locations
Website
http://www.pharmaxis.com.au
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Table of Contents

Key People

  • Edward J. Rayner

    Edward J. Rayner, Non Executive Director

    • Malcolm J McComas

      Malcolm J McComas, Independent Chairman

      • Will Delaat, Chairman

        • Gary J Phillips

          Gary J Phillips, Chief Executive Officer

          LocationsView all

          3 locations detected

          • Frenchs Forest, NSW HQ

            Australia

            20 Rodborough Rd

          • Dublin 18, County Dublin

            Ireland

            Paramount Court, Corrig Rd, Sandyford Business Park, Sandyford

          • London, England

            United Kingdom

            Ae Capital Advisers, 25 Moorgate

          Pharmaxis Financials

          Summary Financials

          Gross profit (H1, 2026)
          $3.2M
          Net income (H1, 2026)
          ($6.1M)
          Cash (H1, 2026)
          $10.5M
          EBIT (H1, 2026)
          ($6.1M)

          Competitors and Similar Companies

          Compare competitors

          Footer menu

          Product

          Solutions

          Resources

          Company

          © Craft.co 2026
          Share price data provided by IEX